MAP2K2 L46F
|
Melanoma
|
MAP2K2 L46F
|
Melanoma
|
SNR1611 Resistant: C3 – Early Trials
|
SNR1611 Resistant: C3 – Early Trials
|
MAP2K2 L46F
|
Melanoma
|
MAP2K2 L46F
|
Melanoma
|
dabrafenib Resistant: C3 – Early Trials
|
dabrafenib Resistant: C3 – Early Trials
|